ISSN: 0974-276X
Journal of Proteomics & Bioinformatics
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
 
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Proteomic Analysis of Human Breast Cancer: New Technologies and Clinical Applications for Biomarker Profiling

Bechr Hamrita1 , Hela ben nasr1, Maria Kabbage1, Mounir Trimeche2, Philippe Hamman3, Christelle-Lemaitre Guillier3, Anouar Chaieb1,4, Lotfi Chouchane1 and Karim Chahed1
1Laboratoire d’Immuno-Oncologie Moléculaire, Faculté de Médecine de Monastir; Tunisia
2Departement de Pathologie, Centre Hospitalo-Universitaire Farhat-Hached, 4002 Sousse, Tunisia
3Plate Forme Proteomique, Institut de Biologie Moleculaire et Cellulaire, CNRS, 67084 Strasbourg, France
4Service d'Obstétrique et des maladies féminines, Centre Hospitalo-Universitaire-Farhat-Hached, Sousse, Tunisia
Corresponding Author : Bechr Hamrita,
Laboratoire d’Immuno-Oncologie Moléculaire
Faculté de Médecine de Monastir, 5019 Monastir, Tunisia
Tel: +216 73 462 200
Fax: +216 73 230 932
E-mail : bechrhamrita@yahoo.fr
Received February 11, 2010; Accepted March 15, 2010; Published March 15, 2010
Citation: Hamrita B, Nasr HB, Chahed K, Kabbage M, Chouchane L (2010) Proteomic Analysis of Human Breast Cancer: New Technologies and Clinical Applications for Biomarker Profiling. J Proteomics Bioinform 3:091-098. doi: 10.4172/jpb.1000126
Copyright: © 2010 Hamrita B, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Related article at
DownloadPubmed DownloadScholar Google

Visit for more related articles at Journal of Proteomics & Bioinformatics

Abstract

Breast cancer is the most diagnosed cancer in women, accounting for approximately 40,000 deaths annually in the USA. In Tunisia, the incidence of breast cancer is approximately 19 new cases per 100,000 women per year. Significant advances have been made in the areas of detection and treatment, but a significant number of breast cancers are detected late. The enormous progress in proteomics, enabled by recent advances in MS (mass spectrometry), has brought protein analysis back into the limelight of breast cancer research, reviving old areas as well as opening new fields of study like early detection, prognosis, diagnosis, and therapy. Several proteomics technologies have been used to uncover molecular mechanisms associated with breast carcinoma at the global level to discover protein patterns that distinguish disease and disease-free states with high sensitivity and specificity. Breast cancer proteomics has already identified markers of potential clinical interest (such as the molecular chaperone alpha B-crystallin) and technological innovations such as large scale and high throughput analysis are now driving the field. In this review, we discuss the basic features of proteomic technologies, including MS, and we consider the main current applications and challenges of proteomics in breast cancer research, including (i) protein expression profiling of breast tumours, tumour cells, tumour fluids and the auto-immune response of the breast cancer cells. All of these applications continue to benefit from further technological advances, such as the development of proteomics methods, high-resolution, highsensitivity MS, SERPA approach, and advanced bioinformatics for data handling and interpretation.

Keywords
Breast markers; Proteomics; 2-DE; Mass spectrometry; SERPA
Abbreviations
2DE: Two-Dimensional Electrophoresis; SDSPAGE: Sodium Dodecylsulfate-Polyacrylamide Gel Electrophoresis; IEF: Isoelectric Focusing; RBP: Retinol Binding Protein; TTR: Transthyretin; 2D-blotting; western blotting following 2-DE; BC: Breast Cancer; IDCA: Infiltrating Ductal Carcinoma; MALDITOF- MS: Matr ix Assisted Laser Desorption/Ionization Time Of Flight Mass Spectrometry; SERPA: Serological Proteome Analysis.
Introduction
Breast cancer is a leading cause of death among women and a major health problem of public, considering the number of women who are diagnosed and who die annually of this pathology. Its incidence is steadily rising in developing countries. For example, in the USA, breast cancer is estimated to be the most commonly diagnosed neoplasm in women in 2008, as it will account for 26% of all new female cancer cases (Jemal et al., 2008). In addition, it is expected to be the second leading cause of USA cancer deaths in 2008 (Jemal et al., 2008). Age is the most important risk factor, and the incidence of breast cancer is increasing 0.5% annually as the population in the West ages. Other risk factors have been reported including parity, age at the first pregnancy, breastfeeding, age at menarche and age at menopause, oestrogen treatment after menopause, environment, stress, and nutrition. Familial history of breast cancer is another major risk factor, emphasising the role of genetics in this pathology (Hondermarck et al., 2001). The large majority of malignant breast tumors are carcinomas which are divided into two classes: in situ and invasive carcinomas. Invasive carcinomas represent 70-80% of all breast cancer and among these; infiltrating ductal carcinomas (IDCA) are the most aggressive forms and have a poor prognosis (Hondermarck et al., 2001). Histopathologically identical breast cancers show a different biological behavior in terms of aggressiveness, progression, and response to therapy. Thus, there is a great need for new breast cancer biomarkers that might help to detect this cancer at an earlier stage, to uncover prognostically distinct subclasses, and to provide best individual treatment (Hondermarck et al., 2001). Currently, the search for specific cancer-related alterations largely focus upon clinically relevant biologically fluids such as serum, plasma, cell and tissue (Hondermarck et al., 2001).
Proteomics with the recent advances in mass spectrometry is considered as a powerful analytical method for deciphering proteins expressions alterations as a function of disease progression (Hondermarck et al., 2001). Recently, proteomicsbased analyses of breast serum and tissue lysates have resulted in the finding of a number of potential tumor biomarkers providing, therefore, a basis for a better understanding of the breast-cancer development and progression, and eventually serving as diagnostic and prognostic markers (Hondermarck, 2003). Probably the most widely used proteomic technology is the identification of alterations in protein expression between two different samples through comparative two-dimensional gel electrophoresis (2-DE) which provides high-resolution separation of proteins and offers a powerful method for their identification and characterization (Anderson et al., 1996). Proteins of interest can be then characterized by mass spectrometry (Hondermarck, 2003). The goals of these efforts are to improve diagnostic methods by either discovering new serological tests or biomarkers, or to improve pathological analysis using tissue proteomics. Such data would provide the knowledge base for the identification of therapeutic targets and the development of new strategies against breast cancer (Hondermarck et al., 2001). The aim of this review is to illustrate the proteomic technologies that have emerged for comprehensive and high-throughput protein analysis and to provide more detailed of their application in breast cancer research and treatments.
The proteomic tools for identifying molecular markers of the breast
Proteomic analysis can be viewed as an experimental approach to explain the information contained in genomic sequences in terms of the structure, function, and control of biological processes and pathways. Therefore, the proteome reflects the cellular state or the external conditions encountered by a cell. In addition, proteomic analysis can be viewed as a genome-wide assay to differentiate distinct cellular states and to determine the molecular mechanisms that control them (Anderson et al., 1996). Quantitative proteomic analyses can be used to identify the protein content in complex samples such as serum, plasma, cell and tissue extracts and to determine the quantitative difference in abundance for each polypeptide contained in different samples (Anderson et al., 1996). Analyses of the proteomic profiles would impact a wide range of biological and clinical research questions, such as the systematic study of biological processes and the discovery of clinical biomarkers for detection and diagnosis. Biomarkers can be defined as cellular, biochemical, and molecular alterations by which normal, abnormal, or simply biologic processes can be recognized or monitored (Vercoutter-Edouart et al., 2001; Hondermarck, 2003). These alterations should be able to objectively measure and evaluate normal biological process, pathogenic processes (like breast cancer), to a therapeutic intervention. Therefore, proteomic profiling is valuable in the discovery of biomarkers as the proteome reflects both the intrinsic genetic program of the cell and the impact of its immediate environment. Protein expression and function are subject to modulation through transcription as well as through translational and posttranslational events. In addition, breast markers can be subtle changes in molecular structures, for instance al terations of post-translat ion modifications, which often can only be examined at the protein level (Shevchenko et al., 1996; Francois et al., 2001). Currently investigators are pursuing three different approaches to develop a technology to study biomarkers with increased sensitivity and specificity. The first is to improve on currently used or known biomarkers. The second approach is to discover and validate novel biomarkers with greater sensitivity and specificity. The third approach is to use a panel of biomarkers, either by combining several individually identified biomarkers or by using mass spectrometry to identify a pattern of protein peaks in sera that can be used to predict the presence of cancer (François et al., 2001).
Utility and recent advancements in the proteomics approaches
In recent years, the combination of 2-DE and MS has been utilized extensively for proteomics research in medicine. The power of the 2-DE-based technology was recognized by the research community early on, and scientists from various disciplines were attracted to the field of proteomics. The information obtained by the 2-DE-based approach is high because a number of specific protein attributes can be determined. Thousands of proteins can be resolved and visualized simultaneously on a single 2-DE gel; for each protein, the isoelectric point, MW, and the relative quantity can be measured (Figure 1, Figure 2). High-resolution capabilities of 2-DE allow the separation and detection of post-translationally modified proteins. In many instances, post-translationally modified proteins can be readily located in 2-DE gels because they appear as distinctive horizontal or vertical clusters of spots. In addition, modified proteins can be revealed by MS analysis, when multiple spots of the same protein are identified. In terms of equipment, the 2-DE-based technology is well suited for research conducted in an academic setting. Most scientists engaged in biological research are familiar with one-dimensional gel electrophoresis; 2-DE, while more complex and labor-intensive, is a natural extension of their expertise. In addition, 2-DE equipment is relatively inexpensive and can therefore be supported by individual project grants. Access to other essential components, such as mass spectrometers and bioinformatics resources, can be obtained through shared-instrumentation and/or fee-forservice facilities, which are in place at many academic institutions. Thus, many investigators from various scientific disciplines can incorporate proteomics into their research programs. A number of modifications to the 2-DE-based methodology have been introduced and explored, like:
Introduction of immobilized pH gradient gels (IPG strips) for IEF has played a major role for the widespread application of 2- DE gels (Hanash et al., 2000). However, this strategy, which increases sample requirements and offers lower throughput, may not be practical for many proteomics studies (Hondermarck et al., 2001).
Recently, laser capture microdissection (LCM) technology has been introduced to enable the isolation of pure cell populations (Cowherd et al., 2004). The compatibility of LCM with 2-DEbased proteomic analysis of human tumors has been demonstrated (Mathélin et al., 2006).
Pre-fractionation of proteins prior to 2-DE separation can be carried out to reduce the complexity of the protein mixtures and/ or to isolate specific sub-sets of proteins, like the albumin and immunoglobulin in the serum or in the plasma (Hamrita et al., 2009; Bjorhall et al., 2005).
MALDI-TOF-MS remains an important tool for protein identification because of its high throughput, sensitivity, and high mass accuracy (Domon et al ., 2006). Numerous advancements have been made in MALDI-TOF instrumentation and new-generat ion, automated MALDI-TOF mass spectrometers are commercially available. These highthroughput systems are run without operator intervention, and incorporate algorithms for iterative optimization of instrument parameters during data acquisition. Improved software tools for the detection of monoisotopic peaks in MALDI-TOF spectra have also been developed (Chaurand et al., 2006). Another type of newly developed MS instrumentation combines electrospray ionization (ESI) with a quadrupole time-of-flight (QTOF) analyzer. The QTOF analyzer can be coupled with MALDI, and MALDI-QtOF-MS was shown to be a promising new tool for proteomics. The latest generation of proteomics instrumentation also includes the MALDI tandem-time-of-flight (MALDI-TOF/ TOF) mass spectrometer. The major advantages of the MALDITOF/ TOF instrument are ultra-high throughput, high sensitivity, and high-energy collision-induced dissociation capabilities that provide enhanced peptide-sequence information.
Protein signatures: 2-DE and Mass spectrometry
High-throughput proteomic methodologies have the potential to revolutionize protein biomarker discovery and to allow for multiple proteins markers to be assayed simultaneously. With the significant advances in 2-DE and mass spectrometry, protein biomarker discovery has become one of the central applications of proteomics (Srinivas et al., 2001). Most studies followed an approach in which a cocktail was used to solubilize the protein contents of an entire cell population, tissue or biological fluid (serum, plasma), followed by separation of the protein contents of the lysate using 2-DE gels and visualization of the separated proteins using silver staining (Shevchenko et al., 1996). This approach is used to find new biomarkers and treatment targets for various disease conditions, including breast carcinomas (Anderson et al., 1996; François et al., 2001; Hondermarck et al., 2001). New methods for rapid identification of both known and unknown proteins are under development. Matrix-assisted laser desorption and ionization with time-of-flight detection mass spectrometry (MS) (MALDI-TOF) and surface-enhanced laser desorption and ionization with time-of-flight spectrometry (SELDI-TOF) are two of the methods currently being employed. MALDI techniques immobilize protein samples in an energy absorbing matrix (chemical) on a chip or plate. The entire repertoire of proteins in the sample interacts with the matrix from which a selected subset of proteins is bound to, a function of the composition of the selected matrix. MALDI analysis is well suited for resolution of proteins <20 kDa, the low molecular weight proteome, a heretofore poorly dissected information reserve. Conversely, SELDI technology uses selective surfaces for binding a subset of proteins based on absorption, partition, electrostatic interaction or affinity chromatography on a solidphase protein chip surface (Issaq et al., 2002). The detector plate records the intensity of the signal at a given m/z value, and a spectrum is generated (Wright et al., 1999). The different peaks in the spectrum correspond to different m/z protein species. This datastream of information can be coupled with datastreams from a series of test subjects and complex bioinformatics to define discriminants for cancer detection. A variety of artificial intelligence bioinformatic tools have been demonstrated to successfully develop discriminating signatures for different cancers, and early work is ongoing to demonstrate the applicability of this concept to other diseases.
Markers Identified Using Proteomics
Sera samples
The accessibility of blood samples and the routine drawing of blood for other analyses make the use of plasma and serum ideal candidates for the identification of biomarkers for clinical studies (Hanash et al., 2008; Zhang et al., 2002). Searching for human plasma/serum alterations using 2-DE with regard to neoplastic disease has been extensively investigated. As early as 1974, 2- DE was carried to look for differences between protein patterns of individuals suffering cancer (Wright, 1974). Since, several markers were characterized and are currently used for diagnosis. As an example, kallikreins, a family of secreted serine proteases were highly associated with ovarian carcinoma as well as with breast and prostate cancers (Yousef and Diamandis, 2001). Other markers are effective for diagnosing primary or advanced neoplastic diseases. The carcinoembryonic antigen (CEA) is used for detecting colorectal cancer, Her2/neu, CA 15-3 and CA 27- 29 for advanced breast cancer (Diamandis, 1996; Buzdor and Hortobagy, 1999). One of the studies to suggest that 2-DE could be used to distinguish protein spot patterns between disease states and control was by Chahed et al. ( 2004). Plasma was compared between blood donor controls and from patients with breast carcinoma. Several proteins were up-regulated in all of the breast cancer samples compared to that of healthy controls. 2-DE investigations showed elevated levels of acute phase proteins such as haptoglobin (β-chain), serum amyloid P, α1-antitrypsin, α1-antichymotrypsin and α1- acidic glycoprotein in plasma from patients diagnosed with breast cancer (Figure 1). Two other proteins, highly elevated in cancer plasma, were identified as Retinol Binding Protein (RBP) and transthyretine (TTR) (Chahed et al., 2004). In an effort to identify other potential serum markers for breast cancer, proteomic analysis with 2-DE and MS has been used. Protein extracts expressed in the serum of breast cancer patients after depletion of high abundance proteins (with AffiGel-blue) were compared to sera from healthy women using proteomic approaches. By comparing 2-DE profiles between tumor and non-tumor samples and using MALDI-TOF mass spectrometry of their trypsinized fragments, we report herein the identification of two proteins of interest, namely haptoglobin precursor and alpha-1- antitrypsin precursor, whose expression was altered in sera from infiltrating ductal breast carcinoma patients (Hamrita et al., 2009). Several others studies have been reported to differentiate between serum or plasma of breast cancer patients, patients with benign breast disease and/ or healthy controls (Tomaiuolo et al., 2009; François et al., 2001). Becker et al, (2004), investigated whether the BRCA-1 mutation was reflected by the serum proteome. Multiple SELDITOF MS peaks were significantly different in expression between breast cancer patients with and without the BRCA-1 mutation (Becker et al., 2004). However, as none of these peaks were structurally identified, their association to the BRCA-1 gene remains unclear. In other study, Li et al, (2002) observed three serum peaks to distinguish patients from controls: one (4.3 kDa) decreased and two (8.1 and 8.9 kDa) increased in patients. These peaks were structurally identified as a fragment of inter-alphatrypsin inhibitor heavy chain H4 (ITIH4, 4.3 kDa), C3a desarginine (C3adesArg, 8.9 kDa) and a C-terminal truncated form thereof (C3adesArgD8, 8.1 kDa) (Li et al., 2002; Li et al., 2005). The latter study also reported a decreased 8.9 kDa C3adesArg expression in breast cancer, whereas in all previous studies, this fragment was found increased (Li et al., 2002; Li et al., 2005). In addition, the 4.3 kDa ITIH4 fragment was one of the several ITIH4 fragments found increased in breast cancer by Regarding the inconsistent regulation observed across multiple studies, the definitive value of the different ITIH4 fragments, C3adesArg, and C3adesArgD8 in the diagnosis of breast cancer cannot be determined yet. The fibrinogen fragment, though increased in the breast cancer serum peptidome, was found decreased in breast cancer plasma and reverted to normal values after surgical extirpation of the tumour (Shi et al., 2006). The difference between study results most likely originates from the biological matrix investigated, as plasma differs from serum by inhibition of the coagulation cascade, by which fibrinogen is generated. Other recently identified breast cancer biomarkers using SELDI include Hsp27, 14-3-3 sigma, and mammaglobin/ lipophilin B complex (Belluco et al., 2007).
Cells and Tissue samples
Separation and analysis of proteins from cells, tissue samples and breast tumour biopsies has proved very successful in identifying novel markers. In our laboratory, we have used an immunoproteomic approach named SERPA to identify tumor antigens that elicit a humoral immune response in patients with breast cancer. Using this methodology, we detected twenty six immunoreactive proteins (antigens) against which sera from newly diagnosed patients with infiltrating ductal carcinomas exhibited reactivity. These protein spots were targeted by mass spectrometry. Among these antigens, peroxiredoxin-2 (Prx-2) belongs to a family of thiol-specific antioxidant proteins that control intracellular H2O2 by reducing reactive oxygen species (ROS) issued from free radicals. Such proteins may have an important role and protect the breast tumor cells against oxidative injury and modulate cell proliferation and apoptosis of malignant cells (Chung et al., 2001). To our best knowledge, thus far, there have been no data on Prx-2 as a factor eliciting humoral immune responses in cancer patients. Mn-SOD and PDI are both antigens that significantly demonstrate a high frequency immunoreaction in breast cancer sera. PDI is often upregulated under stress conditions and is involved in anti-oxidative reactions and during the folding of secretory proteins, as well as, in the catalysis of the formation and isomerization of disulfide bonds. Although the mechanisms for the development of these antibodies in cancer patients remain unknown, their occurrence has been suggested as depending on the amount of their respective antigenic proteins in tumor tissues (Yang et al., 2007). In our hands, expression levels of Mn-SOD and PDI proteins were significantly higher in tumor tissues, suggesting that overexpression of these proteins may be a contributing factor to their immunogenicity (Chahed et al., 2005). This finding, although preliminary, may be further used as a starting point to better understand the mechanisms of generation of theses antibodies in breast carcinogenesis. HSP60 and alpha B-crystallin are two other immunoréactive proteins most commonly observed in the breast cancer cells (MCF-7) (Figure 3, Figure 4). The molecular chaperone HSP60 is involved in protein folding, as well as, in activation of α2β1 integrin which is a major contributing factor in breast cancer progression and metastasis (Barazi et al., 2002). Recently, it has been reported that increased expression of HSP60 in breast tumors may have a prognostic value since it correlates with the presence of lymph node metastasis (Li et al., 2006). The data reported herein appears to confirm this for breast cancer patients as well, and suggest that molecular alterations leading to an immune reaction directed toward antigens related to the system of protein folding may be an important marker in breast carcinogenesis. Prohibitin is another antigen that was recognized in breast cancer cell. Prohibitin is involved in cell cycle control, differentiation and in suppression of tumor progression. In addition, studies have shown that prohibitin interacts with cell cycle regulatory proteins and modulates Rb/E2F, as well as, p53 regulatory pathways (Fusaro et al., 2003). Besides prohibitin, other antigens identified in this study were also known to be involved in apoptosis such as heterogeneous nuclear ribonucleoproteins (hnRNP) K and A2B1. Interestingly, the hnRNPK is involved in the activation of the human c-Myc promoter and enhances cell proliferation and growth of breast cancer cells in an anchorage independent manner (Mandal et al., 2001). Although the mechanisms for the development of immunogenicity against these proteins in cancer are not very clear, there is a growing tide supporting that such apoptosis-related proteins can undergo changes and elicit an autoimmune response in cancer and autoimmune diseases (Levine et al., 1999). Interestingly, the haptoglobin-related protein (Hpr) is another protein that has been reported as a tumor antigen, a mediator of malignant processes and an indicator of progression of disease and response to therapy. In a previous study, Hpr immunoreactivity within breast cancer cells has been shown to localize predominantly in invasive rather than in situ carcinomas and correlates with phenotypically aggressive neoplasia and shorter disease-free survival (Kuhajda et al., 1989). It has been suggested that synthesis and secretion of Hpr by cancer cells might be useful in screening and diagnostic procedures and that this may account for at least one of the mechanisms of developing autoantibodies against this protein (Epelbaum et al., 2008). In the other study, Kabbage et al, (2008) successfully identified the α-B crystallin, Hsp27 and Mn-SOD, which were elevated in breast tumor samples (Kabbage et al., 2008). The molecular chaperone HSP27 and α- B-crystallin, which is a small heat shock protein (HSP), are two dysregulated proteins in tumor tissues. The concomitant upregulation of these HSPs together with α-B-crystallin and HSP27 is not surprising since chaperones are thought to work cooperatively to fulfil their functions (Kiang et al., 1998). Due to the capacity of HSPs to prevent stress-accumulated, unfolded, and nascent protein aggregation, their expression has proven to have important pathological implications such as cell proliferation and disease prognosis (He et al., 2004). The HSP27 is a molecular chaperone whose rate of synthesis increases many folds in response to environmental stress and during malignant transformation (Korneeva et al., 2000). Al though no evidence of posttranslational alterations was pointed out, these isoforms as reported in renal cell carcinomas might reflect phosphorylation or other posttranslational modifications (Korneeva et al., 2000). The role of α-B-crystallin in cancer pathology has been widely discussed with regard to its potential oncogenic role. Previous studies unveiled that this small HSP may constitute a good target for modulating cell death pathways (Sarto et al., 2004). Its expression has been shown to inhibit both the mitochondrial and the receptor death activation pathways of caspase 3 and correlates with TRAIL resistance in a panel of cancer cell lines (Parcellier et al., 2005). This protein may also be an interesting molecular target for exploring the evolution and the origin of breast tumors since higher α-B-crystallin levels were reported in ductal carcinoma in situ, which is an earliest form of detectable breast cancer (Kamradt et al., 2001; Kamradt et al., 2005). The data reported herein appear to confirm this for invasive carcinomas as well. Although further studies are needed to answer how this oncoprotein contributes to breast cancer, the data reported herein highlight the importance of this molecular chaperone in invasive carcinomas as a biomarker that may play a distinctive role in the process of carcinogenesis. The MnSOD is a mitochondrial enzyme that has been reported to protect cells against oxidative stress by increasing the dismutation rate of superoxide anion (O-2) to hydrogen peroxide (H2O2) which is then converted into water by catalase and glutathione peroxidase. The role of this antioxidant enzyme in carcinogenesis is still however controversial and unclear. In fact although, it has been reported to suppress apoptosis and protect cells against several insults, under some circumstances, the Mn-SOD may prevent cell proliferation (Wheeler et al., 2003). Although further studies are needed, the present elevation of Mn-SOD may indicate that the antioxidant defense system has been stimulated in invasive carcinomas of the breast, highlighting the ability of tumor cells to prevent damage due to reactive oxygen species.
Validation of the biomarkers
The end result of proteomic analysis is to have appropriate validation before the marker can reach clinical applications. Once a putative biomarker has been identified, validation using additional measurements and compound identification is necessary (Anderson and Anderson, 2002). For example, one can repeat the analysis at additional time points and determine the temporal correlation of putative biomarkers with the progression of the disease. Determining the timing of the appearance of a biomarker has been shown to be important in assessing a biomarker’s prognostic utility. This fact illustrate that critical issues are needed to be addressed for the validation studies include the specificity and reproducibility of the marker. In the case of cancer tissues and biological fluids, this is further complicated by intra- and inter-cell heterogeneity. The use of tumor tissues or needle biopsies may be problematic because multiple and representative tissue sampling is not always feasible, e.g. tumors in non-accessible sites. To address these problems, a proteomic study realised in our laboratory on breast cancer that combined proteomics and immunohistochemistry with clinical data and correlated the protein database to breast cancer cell heterogeneity within normal tissue with recurrence (Figure 4). More exciting methods are being developed that can compare proteins present in easily accessible biological fluids from patients, which are predictive of disease progression and/or therapeutic response. This approach has been reported for body fluids including serum. However, most current published studies are very preliminary and were conducted in a very small number of samples with no specific marker being carefully validated.
Conclusions
The identification of reliable biomarkers to track breast cancer, which should provide a better classification of tumors, allow for personalized therapy and exciting challenge for the scientific and medical community. Analysis of proteins expressed by serum, plasma and tumors, using novel concepts and methods, should accelerate our quest to attain this goal and bring to light a better and more comprehensive view of the molecular heterogeneity of breast cancers. In this way the proteomics approaches provides powerful tools to study pathological processes or clinically important problems at the molecular level and will have a major impact in the future. Since the introduction of proteomics, 2- DE, SERPA approach and MS have been successfully used in a large number of studies in many biological fields.
References
  1. Anderson NG, Anderson NL (1996) Twenty years of two-dimensional Electrophoresis: past, present and future. Electrophoresis 17: 443-53.  » PubMed » Google Scholar
  2. Anderson NL, Anderson NG (2002) The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Prot 1: 845-867.» CrossRef » PubMed » Google Scholar
  3. Barazi HO, Zhou L, Templeton NS, Krutzsch HC, Roberts DD (2002) Identification of heat shock protein 60 as a molecular mediator of alpha 3 beta 1 integrin activation. Cancer Res 62: 1541-8. » CrossRef » PubMed » Google Scholar
  4. Becker S, Cazares LH, Watson P, Lynch H, Semmes OJ, et al. (2004) Surfacedenhanced laser desorption/ionization time-of-flight (SELDI-TOF) differentiation of serum protein profiles of BRCA-1 and sporadic breast cancer. Ann Surg Oncol 11: 907-914. » CrossRef » PubMed » Google Scholar
  5. Belluco C, Petricoin EF, Mammano E, Facchiano F, Ross-Rucker S, et al. (2007) Serum proteomic analysis identifies a highly sensitive and specific discriminatory pattern in stage 1 breast cancer. Ann Surg Oncol 14: 2470-2476. » CrossRef » PubMed » Google Scholar
  6. Bjorhall K, Miliotis T, Davidsson P (2005) Comparison of different depletion strategies for improved resolution in proteomic analysis of human serum samples. Proteomics 5: 307-317. » CrossRef » PubMed » Google Scholar
  7. Buzdor AU, Hortobagy CN (1999) Breast cancer: in Pinedo HM, Londo DL, Chabner BA eds- Cancer chemotherapy and biological response modifiers. Annual 18, Amsterdam Elsevier-Sciences BV 435- 69.
  8. Chahed K, Hamrita B, Mejdoub H, Remadi S, Chaïeb A, et al. (2004) Two dimensional gel electrophoresis analyses of human plasma proteins. Association of retinol binding protein and transthyretin expression with breast cancer. Gene Ther Mol Biol Vol 8: 539-546. » Google Scholar
  9. Chahed K, Kabbage M, Sabatier L, Ehret-Sabatier L, Lemaitre-Guillier C, et al. (2005) Expression of fibrinogen E-fragment and fibrin E-fragment is inhibited in the human infiltrating ductal carcinoma of the breast: The two-dimensional electrophoresis and MALDI-TOF-mass spectrometry analyses. Int J Oncol 27: 1425-31. » PubMed » Google Scholar
  10. Chaurand P, Norris JL, Cornett DS, Mobley JA, Caprioli RM (2006) New developments in profiling and imaging of proteins from tissue sections by MALDI mass spectrometry. J Proteome Res 5: 2889- 2900. » CrossRef » PubMed » Google Scholar
  11. Chung YM, Yoo YD, Park JK, Kim YT, Kim HJ (2001) Increased expression of peroxiredoxin II confers resistance to cisplatin. Anticancer Res 21: 1129-33. » CrossRef » PubMed » Google Scholar
  12. Cowherd SM, Espina VA, Petricoin EFIII, (2004) Proteomic analysis of human breast cancer tissue with laser-capture microdissection and reverse-phase protein microarrays. Clin Breast Cancer 5: 385-39.  » PubMed » Google Scholar
  13. Diamandis EP (1996) Prognostic markers in breast cancer. Clin Lab News 22: 235-9.  » Google Scholar
  14. Domon B, Aebersold R (2006) Mass spectrometry and protein analysis. Science 312: 212-217.  » Google Scholar
  15. Epelbaum R, Shalitin C, Segal R, Valansi C, Arselan I, et al. (1998) Haptoglobinrelated protein as a serum marker in malignant lymphoma. Pathol Oncol Res 4: 271-6. » CrossRef » PubMed » Google Scholar
  16. Fung ET, Yip TT, Lomas L, Wang Z, Yip C, et al. (2005) Classification of cancer types by measuring variants of host response proteins using SELDI serum assays. Int J Cancer 115: 783-789. » CrossRef » PubMed » Google Scholar
  17. Fusaro G, Dasgupta P, Rastogi S, Joshi B, Chellappan S (2003) Prohibitin induces the transcriptional activity of p53 and is exported from the nucleus upon apoptotic signaling. J Biol Chem 278: 47853-61. » CrossRef » PubMed » Google Scholar
  18. Hamrita B, Chahed K, Kabbage M, Christelle LG, Trimeche M, et al. (2008) Identification of tumor antigens that elicit a humoral immune response in breast cancer patients’ sera by serological proteome analysis (SERPA). Clinica Chimica Acta 393: 95-102. » CrossRef  » PubMed » Google Scholar
  19. Hamrita B, Chahed K, Trimeche M Christelle LG , Philippe H, et al. (2009) Proteomics-based identification of alpha1-antitrypsin and haptoglobin precursors as novel serum markers in infiltrating ductal breast carcinomas. Clin Chim Acta 404: 111-8. » CrossRef » PubMed » Google Scholar
  20. Hanash S (2000) Biomedical applications of two-dimensional electrophoresis with immobilized pH gradients. Electrophoresis 21: 102-9. » CrossRef » PubMed » Google Scholar
  21. Hanash SM, Pitteri SJ, Faca VM (2008) Mining the plasma proteome for cancer biomarkers. Nature 452: 571-579. » CrossRef » PubMed » Google Scholar
  22. He QY, Chen J, Kung HF, Yuen AP, Chiu JF (2004) Identification of tumorassociated proteins in oral tongue squamous cell carcinoma by proteomics. Proteomics 4: 271-278. » CrossRef » PubMed » Google Scholar
  23. Hondermarck H, Vercoutter-Edouart AS, Révillion F, Lemoine J, El-Yazidi- Belkoura I, et al. (2001) Proteomics of breast cancer for marker discovery and signal pathway profiling. Proteomics 1: 1216-32.  » PubMed » Google Scholar
  24. Hondermarck H (2003) Breast cancer: when proteomics challenges biological complexity. Molecular & Cellular Proteomics 2: 281-291.  » CrossRef » PubMed » Google Scholar
  25. Issaq H, Veenstra T, Conrads T, Felschow D (2002) The SELDI-TOF MS approach to proteomics: protein profiling and biomarker identification. Biochem Biophys Res Commun 292: 587-92. » CrossRef » PubMed » Google Scholar
  26. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2008) Cancer statistics, 2008. CA Cancer J Clin 58: 71-96. » CrossRef » PubMed » Google Scholar
  27. Kabbage M, Chahed K, Hamrita B, Christelle LG, Trimeche M, et al. (2008) Protein Alterations in Infiltrating Ductal Carcinomas of the Breast as Detected by Nonequilibrium pH Gradient Electrophoresis and Mass Spectrometry. J Biomed Biotechnol 564127. » CrossRef » PubMed » Google Scholar
  28. Kamradt MC, Lu M, Werner M, Chen F, Strohecker A, et al. (2005) The small heat shock protein αB-crystallin is a novel inhibitor of TRAIL induced apoptosis that suppresses the activation of caspase-3. J Biol Chem 280: 11059-11066. » CrossRef  » PubMed » Google Scholar
  29. Kamradt MC, Chen F, Cryns VL (2001) The small heat shock protein αBcrystallin negatively regulates cytochrome c and caspase-8-dependent activation of caspase-3 by inhibiting its autoproteolytic maturation. J Biol Chem 276: 16059-16063. » CrossRef » PubMed » Google Scholar
  30. Kiang JG, Tsokos GC (1998) Heat shock protein 70 kDa: molecular biology, biochemistry, and physiology. Pharmacology & Therapeutics 80: 183-201. » CrossRef » PubMed » Google Scholar
  31. Korneeva I, Bongiovanni AM, Girotra M, Caputo TA, Witkin SS (2000) IgA antibodies to the 27 kDa heat-shock protein in the genital tracts of women with gynecologic cancers. Int J Cancer 87: 824- 828. » CrossRef » PubMed » Google Scholar
  32. Kuhajda FP, Katumuluwa AI, Pasternack GR (1989) Expression of haptoglobinrelated protein and its potential role as a tumor antigen. Proc Natl Acad Sci USA 86: 1188-92. » CrossRef  » PubMed » Google Scholar
  33. Le Naour F, Misek DE, Krause MC, Deneux L, Giordano TJ, et al. (2001) Proteomics-based identification of RS/DJ-1 as a novel circulating tumor antigen in breast cancer. Clin Cancer Res 7: 3325-7. » CrossRef  » PubMed » Google Scholar
  34. Levine JS, Koh JS (1999) The role of apoptosis in autoimmunity: immunogen, antigen, and accelerant. Semin Nephrol 19: 34-47.  » PubMed » Google Scholar
  35. Li DQ, Wang L, Fei F, Hou YF, Luo JM, et al. (2006) Identification of breast cancer metastasis-associated proteins in an isogenic tumor metastasis model using two-dimensional gel electrophoresis and liquid chromatography-ion trap-mass spectrometry. Proteomics 6: 3352-68. » CrossRef » PubMed » Google Scholar
  36. Li J, Orlandi R, White CN, Rosenzweig J, Zhao J, et al. (2005) Independent validation of candidate breast cancer serum biomarkers identified by mass spectrometry. Clin Chem 51: 2229-2235. » CrossRef » PubMed » Google Scholar
  37. Li J, Zhang Z, Rosenzweig J, Wang YY, Chan DW, et al. (2002) Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 48: 1296-1304. » CrossRef » PubMed » Google Scholar
  38. Mandal M, Vadlamudi R, Nguyen D, Wang RA, Costa L, et al. (2001) Growth factors regulate heterogeneous nuclear ribonucleoprotein K expression and function. J Biol Chem 276: 9699-704. » CrossRef » PubMed » Google Scholar
  39. Mathelin C, Cromer A, Wendling C, Tomasetto C, Rio MC, et al. (2006) Serum biomarkers for detection of breast cancers: a prospective study. Breast Cancer Res Treat 96: 83-90. » CrossRef » PubMed » Google Scholar
  40. Mathelin C, Tomasetto C, Cromer A, Rio MC (2006) Protéome et cancer du sein. Gynécologie Obstétrique & Fertilité 34: 1161-69. » CrossRef » PubMed » Google Scholar
  41. Parcellier A, Schmitt E, Brunet M, Hammann A, Solary E, et al. (2005) Small heat shock proteins HSP27 and α-B-crystallin: cytoprotective and oncogenic functions. Antioxid Redox Signa 7: 404-413. » CrossRef » PubMed » Google Scholar
  42. Sarto C, Valsecchi C, Magni F, Tremolada L, Arizzi C, et al. (2004) Expression of heat shock protein 27 in human renal cell carcinoma. Proteomics 4: 2252- 2260. » CrossRef » PubMed » Google Scholar
  43. Shevchenko A, Wilm M, Vorm O, Mann M (1996) Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal Chem 68: 850- 8.  » PubMed » Google Scholar
  44. Shi Q, Harris LN, Lu X, Li X, Hwang J, et al. (2006) Declining plasma fibrinogen alpha fragment identifies HER2-positive breast cancer patients and reverts to normal levels after surgery. J Proteome Res 5: 2947-2955. » CrossRef » PubMed » Google Scholar
  45. Song J, Patel M, Rosenzweig CN, Chan-Li Y, Sokoll LJ, et al. (2006) Quantification of fragments of human serum inter-alpha-trypsin inhibitor heavy chain 4 by a surface-enhanced laser desorption/ionization-based immunoassay. Clin Chem 52: 1045-1053. » CrossRef » PubMed » Google Scholar
  46. Srinivas PR, Srivastava S, Hanash S, Wright GL Jr (2001) Proteomics in Early Detection of Cancer. Clinical Chemistry 47: 901-11.  » Google Scholar
  47. Tomaiuolo M, Vecchione G, Margaglione M, Pisanelli D, Grandone E (2009) Stable-isotope dilution LC-ESI-MS/MS techniques for the quantification of total homocysteine in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 877: 3292-9. » CrossRef » PubMed » Google Scholar
  48. Vercoutter-Edouart AS, Lemoine J, Bourhis X, Louis H, Boilly B, et al. (2001) Proteomic analysis reveals that 14-3-3 sigma is down-regulated in human breast cancer cells. Cancer Res 61: 76-807. » CrossRef » PubMed » Google Scholar
  49. Villanueva J, Shaffer DR, Philip J, Chaparro CA, Erdjument-Bromage H, et al. (2006) Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest 116: 271-284. » CrossRef » PubMed » Google Scholar
  50. Wheeler MD, Smutney OM, Samulski RJ (2003) Secretion of extracellular superoxide dismutase from muscle transduced with recombinant adenovirus inhibits the growth of B16 melanomas in mice. Mol Cancer Res 1: 871-881. » CrossRef » PubMed » Google Scholar
  51. Wright GJ, Cazares L, Leung S, Nasim S, Adam B, et al. (1999) Protein-Chip surface enhanced laser desorption/ionization (SELDI) mass spectrometry: a novel protein biochip technology for detection of prostate cancer biomarkers in complex protein mixtures. Prostate Cancer Prostatic Dis 2: 264-76. » Google Scholar
  52. Wright GL (1974) Two dimensional acrylamide gel electrophoresis of cancer patient serum proteins. Ann Lab Sci 4: 281-293. » PubMed » Google Scholar
  53. Yang F, Xiao ZQ, Zhang XZ, Li C, Zhang PF, et al. (2007) Identification of tumor antigens in human lung squamous carcinoma by serological proteome analysis. J Prot Res 6: 751-8. » CrossRef » PubMed » Google Scholar
  54. Yousef GM, Diamandis FP (2001) The new human tissue kallikrein gene family: structure, function and association to disease. Endocr Rev 22: 148-204. » CrossRef » PubMed » Google Scholar
  55. Zhang L, Rosenzweig J, Wang Y, Chan D (2002) Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 48: 1296-304. » CrossRef » PubMed » Google Scholar
Select your language of interest to view the total content in your interested language
 
Share This Article
   
 
   
 
Relevant Topics
Disc Applications of Bioinformatics
Disc Bacterial transcriptome
Disc Bioinformatics Algorithms
Disc Bioinformatics Databases
Disc Bioinformatics Tools
Disc Cancer Pharmacogenomics
Disc Cancer Proteomics
Disc Clinical Pharmacogenomics
Disc Clinical Proteomics
Disc Cluster analysis
Disc Comparative genomics
Disc Comparative proteomics
Disc Comparative transcriptomics
Disc Computational drug design
Disc Current Proteomics
Disc Data algorithms
Disc Data mining applications in genomics
Disc Data mining applications in proteomics
Disc Data mining in drug discovery
Disc Data mining tools
Disc Data modelling and intellegence
Disc Data warehousing
Disc Drug Dosage Formulations
Disc Drug Toxicity and Efficacy
Disc Epigenetics
Disc Epigenomic studies
Disc Gene Expression profiling
Disc Gene polymorphism
Disc Genome annotation
Disc Genomic Targets
Disc Genomic data mining
Disc Genomic data warehousing
Disc Glycome
Disc Human Proteome Project Applications
Disc Immune Disorders
Disc Individualized Medicine
Disc Mapping of genomes
Disc Mass Spectrometry in Proteomics
Disc Meta genomics
Disc Metabolome
Disc Microarray
Disc Microarray Proteomics
Disc Molecular and Cellular Proteomics
Disc Mouse transcriptome
Disc Non coding MRNA
Disc Personalized Medicine Studies
Disc Pharmacoeconomics in Drug Development
Disc Pharmacogenetics
Disc Pharmacogenomic Biomarker
Disc Pharmacogenomics Applications
Disc Pharmacogenomics Future Medicine
Disc Pharmacogenomics and Personalized Medicine
Disc Pharmacogenomics for Patient Care
Disc Pharmacoproteomics in Drug development
Disc Profiling
Disc Protein Sequence Analysis
Disc Protein engineering
Disc Proteogenomics
Disc Proteome
Disc Proteome Profiling
Disc Proteomic Analysis
Disc Proteomic Biomarkers
Disc Proteomics Clinical Applications
Disc Proteomics Research
Disc Proteomics Science
Disc Proteomics and Pharmacodynamics
Disc Proteomics data warehousing
Disc Python for Bioinformatics
Disc Quantitative Proteomics
Disc RNA sequencing
Disc RNA sequencing and analysis
Disc Sequencing
Disc Small RNA Sequencing
Disc Statistical data mining
Disc Transcripotme
Disc Transcriptional Attenuation
Disc Transcriptional Regulation
Disc Transcriptome analysis
Disc Translational Medicine
 
Recommended Journals
Disc Transcriptomics Journal
Disc Pharmacogenomics Journal
Disc Data Mining Journal
  View More»
 
Recommended Conferences
Disc 6th Bioinformatics Conference
August 22-23, 2016 Philadelphia, Pennsylvania, USA
Disc 7th International Conference and Expo on Proteomics
October 24-26, 2016 Rome, Italy
View More»
 
Article Tools
Disc Export citation
Disc Share/Blog this article
 
Article usage
  Total views: 11324
  [From(publication date):
March-2010 - Jun 29, 2016]
  Breakdown by view type
  HTML page views : 7587
  PDF downloads :3737
 
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

 
OMICS International Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
 
 
OMICS International Conferences 2016-17
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings
 
 

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

agrifoodaquavet@omicsinc.com

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

clinical_biochem@omicsinc.com

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

business@omicsinc.com

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

chemicaleng_chemistry@omicsinc.com

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

environmentalsci@omicsinc.com

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

engineering@omicsinc.com

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

generalsci_healthcare@omicsinc.com

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

genetics_molbio@omicsinc.com

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

immuno_microbio@omicsinc.com

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

omics@omicsinc.com

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

materialsci@omicsinc.com

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

mathematics_physics@omicsinc.com

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

medical@omicsinc.com

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

neuro_psychology@omicsinc.com

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

pharma@omicsinc.com

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

social_politicalsci@omicsinc.com

1-702-714-7001 Extn: 9042

 
© 2008-2016 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version